News | February 08, 2024
MIRA Pharmaceuticals announces collaboration with Pharmaseed
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Dr Jitendra Singh launches API Chapter of AFMC, Pune; inaugurates the first annual conference of API-AFMS Continuing Medical Education (CME) on “Emerging trends in the practice of Medicine”
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
